BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
View BioWorld MedTech
Home » Hungry Gut first of four phenotype tests aimed at fine tuning obesity treatments
To read the full story, subscribe or sign in.

Hungry Gut first of four phenotype tests aimed at fine tuning obesity treatments

April 13, 2023
By David Godkin
Phenomix Sciences Inc. has launched a first-of-its-kind test that could provide precision medicine treatment options for patients suffering from a particular form of obesity. Key to the saliva-based Hungry Gut test for patients still hungry after eating is the science of phenotyping enabling specialists to determine genetic sources for this and other distinct obesity conditions.
Medical technology U.S.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing